Rachel Salzman, DVM

Dr. Salzman serves as Chief Scientific Officer of The Stop ALD Foundation (SALD), and has held this position since 2001. SALD is a non-profit Medical Research Organization dedicated to employing entrepreneurial approaches and innovative methodology towards effective therapies, cures, and prevention of x-linked adrenoleukodystrophy (ALD), an often fatal neurodegenerative disease.

The biomedical interests of the Foundation include gene therapy, hematopoietic stem cells, mesenchymal and other adult stem cells, genomics, and small molecules. In this context SALD made critical contributions to the groundbreaking ex vivo lenti trial conducted in France.

Dr. Salzman also consults for large pharma and biotech in the field of drug development, including preclinical and clinical analysis in a variety of therapeutic areas including oncology, metabolic disease, CNS disorders, and orphan indications.  Prior to these roles, Rachel worked in private veterinary practice in both large and small animal medicine.  She has a D.V.M. from Oklahoma State University and a B.S. from Rutgers University.


Board & Officers

The ASGCT Board of Directors and the Society's officers have full responsibility for the management, direction and control of the Society.

22nd Annual Meeting
April 29 – May 2 | Washington D.C.